Gardado en:
Detalles Bibliográficos
Main Authors: Caldes, T, Godino, J, de la Hoya, M, García Carbonero, I, Perez Segura, P, Eng, C, Benito, M, Diaz Rubio, E
Formato: Recurso digital
Idioma:
Publicado: Zenodo 2002
Subjects:
Acceso en liña:https://doi.org/10.1002/ijc.10240
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
_version_ 1866901098711744512
author Caldes, T
Godino, J
de la Hoya, M
García Carbonero, I
Perez Segura, P
Eng, C
Benito, M
Diaz Rubio, E
author_facet Caldes, T
Godino, J
de la Hoya, M
García Carbonero, I
Perez Segura, P
Eng, C
Benito, M
Diaz Rubio, E
contents <p>HNPCC is an autosomal dominantly inherited cancer-susceptibility syndrome that confers an increased risk for colorectal cancer and endometrial cancer at a young age. It also entails an increased risk of a variety of other tumors, such as ovarian, gastric, uroepithelial and biliary tract cancers. The underlying pathogenic mutation lies in 1 of the 5 known DNA MMR genes (MSH2, MLH1, PMS1, PMS2 and MSH6). We screened a total of 140 individuals from 56 Spanish families with suspected HNPCC for mutations in the DNA mismatch repair genes MLH1 and MSH2, using DGGE and direct DNA sequencing. Families were selected on the basis of a history of HNPCC-related tumors or the occurrence of other associated tumors in members besides the index case affected with colorectal cancer. We detected 14 definite pathogenic germline mutations, 9 in MLH1 and 5 in MSH2 in 13 unrelated families selected by the Amsterdam criteria and Bethesda guidelines (1 family carries 2 mutations) and 3 missense mutations in 3 unrelated families selected by the Amsterdam criteria. Among the 17 germline mutations noted in the Spanish cohort, 10 are novel, 7 in MLH1 and 3 in MSH2, perhaps demonstrating different mutational spectra in the Spanish population, where no founder mutation has been identified. Based on our results, we suggest that in the Spanish population not only HNPCC families fulfilling the Amsterdam criteria but also those following Bethesda guidelines should undergo genetic testing for MSH2 and MLH1 mutations.</p>
format Recurso digital
id zenodo_https___doi_org_10_1002_ijc_10240
institution Zenodo
language
publishDate 2002
publisher Zenodo
record_format zenodo
spellingShingle Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain
Caldes, T
Godino, J
de la Hoya, M
García Carbonero, I
Perez Segura, P
Eng, C
Benito, M
Diaz Rubio, E
Adaptor Proteins, Signal Transducing
Adult
Age of Onset
Carrier Proteins
Colorectal Neoplasms, Hereditary Nonpolyposis
DNA Mutational Analysis
DNA, Neoplasm
DNA-Binding Proteins
female
Germ-Line Mutation
Humans
Male
Microsatellite Repeats
Middle Aged
MutL Protein Homolog 1
MutS Homolog 2 Protein
Neoplasm Proteins
Pedigree
Polymerase Chain Reaction
Proto-Oncogene Proteins
Spain
<p>HNPCC is an autosomal dominantly inherited cancer-susceptibility syndrome that confers an increased risk for colorectal cancer and endometrial cancer at a young age. It also entails an increased risk of a variety of other tumors, such as ovarian, gastric, uroepithelial and biliary tract cancers. The underlying pathogenic mutation lies in 1 of the 5 known DNA MMR genes (MSH2, MLH1, PMS1, PMS2 and MSH6). We screened a total of 140 individuals from 56 Spanish families with suspected HNPCC for mutations in the DNA mismatch repair genes MLH1 and MSH2, using DGGE and direct DNA sequencing. Families were selected on the basis of a history of HNPCC-related tumors or the occurrence of other associated tumors in members besides the index case affected with colorectal cancer. We detected 14 definite pathogenic germline mutations, 9 in MLH1 and 5 in MSH2 in 13 unrelated families selected by the Amsterdam criteria and Bethesda guidelines (1 family carries 2 mutations) and 3 missense mutations in 3 unrelated families selected by the Amsterdam criteria. Among the 17 germline mutations noted in the Spanish cohort, 10 are novel, 7 in MLH1 and 3 in MSH2, perhaps demonstrating different mutational spectra in the Spanish population, where no founder mutation has been identified. Based on our results, we suggest that in the Spanish population not only HNPCC families fulfilling the Amsterdam criteria but also those following Bethesda guidelines should undergo genetic testing for MSH2 and MLH1 mutations.</p>
title Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain
topic Adaptor Proteins, Signal Transducing
Adult
Age of Onset
Carrier Proteins
Colorectal Neoplasms, Hereditary Nonpolyposis
DNA Mutational Analysis
DNA, Neoplasm
DNA-Binding Proteins
female
Germ-Line Mutation
Humans
Male
Microsatellite Repeats
Middle Aged
MutL Protein Homolog 1
MutS Homolog 2 Protein
Neoplasm Proteins
Pedigree
Polymerase Chain Reaction
Proto-Oncogene Proteins
Spain
url https://doi.org/10.1002/ijc.10240